ClinicalTrials.gg
Enrolling by invitationNCT06409741PENINSULAUpdated Jan 1, 2025

PrEveNtion of Biliary Events After Acute Pancreatitis in NonSUrgicaL PAtients: PENINSULA Trial

An interventional study of Biliary sphincterotomy in Acute Pancreatitis Due to Gallstones and Acute Pancreatitis, sponsored by Hospital General Universitario de Alicante. Enrolling by invitation at 5 sites in Spain. Per ClinicalTrials.gov, last updated 2025-01-01.

Sponsored by Hospital General Universitario de Alicante · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Pancreatitis with a site in Spain — 5 open to participants now, 5 under way, 1 of them phase 3. Pancreatitis · Spain.

Planned enrollment
8th of 13
126 · median 249
Started
2024
with 1 other
No phase
6 of 21
3 open now
Registered
20th of 21
by date
Lead sponsor
3 of 21
Hospital General Universitario de Alicante

Among the 21 studies in Pancreatitis with a site in Spain, this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 6 with no phase, and was the 20th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

5 of the 21 studies in Pancreatitis with a site in Spain are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Pancreatitis with a site in Spain, or all of them as a file.
02

Study summary

Acute pancreatitis (AP) is a common condition and its main etiology is biliary. Cholecystectomy is the standard preventive treatment for recurrence of AP after admission. However, due to an increasingly older population and increased patient comorbidity, it is not always a possible option these days. If cholecystectomy is not performed, there is a significant risk for a recurrence of a biliopancreatic event (pancreatitis, biliary colic, choledocholithiasis, cholecystitis or cholangitis) of around 50% in the first year. This can lead to further episodes of pain, patient readmissions, and a reduced quality of life. Additionally, frequent readmissions can create a high cost burden on the health system. Currently, certain clinical guidelines propose biliary sphincterotomy as an alternative for patients in whom surgery is not feasible. However, this recommendation is based on retrospective studies with small sample size and the adherence to this recommendation is very low (12-23%).

The goal of this clinical trial is to evaluate the recurrence of biliopancreatic events in the first year after admission for an acute biliary pancreatitis episode in patients that are not suitable for surgery. The main question it aims to answer is:

Does biliary sphincterotomy prevent biliopancreatic event recurrence in non surgical patients after an episode of biliary acute pancreatitis?

Researchers will compare biliary sphincterotomy vs conservative treatment to see if there is a reduction in biliopancreatic events during the first year after admission for acute pancreatitis in non surgical patients.

Participants will be randomized to conservative treatment or biliary sphincterotomy and will be followed up for one year at 1 month, 6 months and 12 months to evaluate recurrence of BPE, readmissions, quality of life and mortality. Security of the technique will also be assessed in this specific population.

Read the detailed description

Our working hypothesis is that endoscopic treatment with biliary sphincterotomy will reduce the number of biliopancreatic events compared to conservative treatment in patients with non-operable biliary acute pancreatitis (AP) due to a high surgical risk or in those patients who refuse surgery.

The primary aim is to assess the recurrence of the combined variable of biliopancreatic events (BPE) (biliary colic, cholangitis, choledocholithiasis, acute cholecystitis or AP) of the endoscopic sphincterotomy strategy during the follow-up time after diagnosis of AP of biliary origin in inoperable patients with respect to conservative treatment.

This is a randomized, multicenter, open-label, nationwide, intention-to-treat clinical trial. Patients will be randomized 1:1 to the two treatment groups stratified by center and AP severity.

Centers considered to participate as collaborators centers will need to have an endoscopy unit with ERCP availability that perform more than 150 ERCPs/year, and endoscopists trained in this technique. Patient inclusion and exclusion criteria is specified in a specific section of the protocol.

For the inclusion of patients, after diagnosis of biliary AP (BAP), and having ruled cholecystectomy as a possibility for the patient because of high surgical risk (after evaluation by surgery or anesthesia) or patient's refusal to undergo cholecystectomy, the absence of choledocholithiasis will be confirmed by MRCP or EUS.

If the patient fulfills these requirements, in addition to all the previous inclusion criteria and none of the exclusion criteria, and agrees to participate in the study and signs the informed consent the patient will be included and randomized.

This randomization will be carried out in each of the collaborating centers and the patient will be assigned to a treatment group following the random assignment method.

The randomization of patients to each of the treatment groups will be carried out centrally by the REDCap software; REDCap is a program that offers an online electronic data collection notebook. It will be stratified by center and by severity of BAP (mild, moderate or severe according to the Revised Atlanta Classification).

Patients will be randomized to receive ERCP biliary sphincterotomy or conservative management. 63 patients will be allocated to each group. An interim safety analysis is proposed, which will be evaluated by an independent committee of 3 persons, with experience in complications associated with ERCP and knowledge of biliopancreatic pathology, once 50% of the sample reaches 6 months of follow-up. In the event that in this first analysis the risks of treatment outweigh the benefits, according to the decision of the safety committee, the study could be stopped. Also, in the event that at this point there are statistically significant differences in favor of treatment by biliary sphincterotomy with respect to the primary outcome, recruitment can be stopped and the study stopped early.

In the group assigned to receive endoscopic treatment, ERCP for biliary sphincterotomy will be performed during the index admission for acute pancreatitis, prior to discharge or up till one month from discharge.

The procedure will be performed after at least 6 hours of fasting during the index admission, by endoscopists in charge of performing ERCP as usual in the collaborating centers under sedation controlled by endoscopists or anesthesia according to the usual practice of the Endoscopy Unit of each collaborating center.

For ERCP biliary cannulation, the usual techniques available in each center will be used, including advanced cannulation techniques if necessary. The type of papilla, cannulation attempts, time to biliary cannulation and the technique(s) used will be recorded. Possible adverse effects will be recorded. If biliary cannulation is not possible, a new ERCP attempt will be performed within a maximum of one month. If biliary cannulation is still not achieved, it will be counted as a technical failure, maintaining the established clinical follow-up.

The inhospital management of patients with AP in the conservative treatment group, before and after randomization, will be under the care of their responsible physicians on the hospitalization wart at the corresponding collaboration center who will follow the management recommended by the clinical guidelines. Their discharge will be decided by their regular physician.

Periodic follow-up contacts will be made: at one month, at 6 months and at one year. Contacts may be made by face-to-face or telematic visits after consultation with the patient, especially if the patient is institutionalized or has severe mobility problems.

In these contacts, the following will be performed:

  • Record of complications associated with the treatment received and record of BPE developed since the last visit (especially the presence of biliary colic that did not require admission or evaluation in the emergency department). An interview will be conducted aimed at collecting the presence of BPE that did not require admission (such as biliary colic or related pain), recording the type and date of onset. The digital medical record will also be reviewed to record admissions and assessments by the emergency department related or unrelated to BPE and also to assess mortality.
  • EORTQ30 quality of life questionnaire will be conducted in every visit.
03

Conditions studied

  • Acute Pancreatitis Due to Gallstones
  • Acute Pancreatitis

Keywords

  • sphincterotomy
  • acute pancreatitis
  • recurrence
  • conservative treatment
  • biliopancreatic events
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient older than 18 years old.
  • Definitive diagnosis of acute pancreatitis according to the presence of two out of three criteria from the Revised Atlanta Classification. At least 2 criteria: A) Typical pain, B) Amylase or lipase ≥x3 normal limit, C) Imaging evidence compatible with acute pancreatitis).
  • Biliary etiology: (any imaging test that describes gallbladder lithiasis/microlithiasis or biliary sludge).
  • Magnetic resonance cholangiography (MRCP) or endoscopic ultrasound (EUS) is required without evidence of choledocholithiasis.
  • Surgical decision of inoperable patient (if meets one or more of the following criteria: age ≥ 80 years, American Society of Anesthesiology (ASA) III or more, Charlson Comorbidity Index > 5 and/or \< 50 or patient's decision not to undergo surgery. Patient must have been evaluated by general surgery or anesthesia.
  • Signature of the for the study

Exclusion criteria

Exclusion Criteria:

  • Patient refusal to participate in the study.
  • Active ethylism greater than or equal to 5 drinking units per day in men and 3 in women or strong clinical suspicion of ethylism that could be a cause of their AP.
  • Hypertriglyceridemia greater than 400 mg/dl at admission or history of poorly controlled hypertriglyceridemia.
  • Chronic pancreatitis: pancreatic calcifications in body or Wirsung on imaging or Wirsung ≥ 4 mm
  • Biliary condition requiring sphincterotomy during index admission (cholangitis or symptomatic choledocholithiasis) or previous biliary sphincterotomy.
  • Previous cholecystectomy
  • Actual use of ursodeoxycholic acid
  • Gastrointestinal tract anatomy altered by previous hepatobiliary or upper gastrointestinal surgery.
  • Inability to tolerate endoscopy sedation, perforation of the digestive tract or other to endoscopy.
  • Coagulopathy with uncorrectable > 1.5 or uncorrectable thrombocytopenia \< 50000/mm3.
  • Other concomitant diagnoses on admission (liver abscesses, biliopancreatic neoplasia, acute cholecystitis).
  • Hemodynamic instability.
  • Baseline ≥4
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
126 participants (estimated)

Study arms

  • Active comparator
    Biliary sphincterotomy

    In the group assigned to receive endoscopic treatment, ERCP for biliary sphincterotomy will be performed during the index admission for acute pancreatitis, prior to discharge or up till one month from discharge. The procedure will be performed after at least 6 hours of fasting during the index admission, by endoscopists in charge of performing ERCP as usual in the collaborating centers under sedation controlled by endoscopists or anesthesia according to the usual practice of the Endoscopy Unit of each collaborating center. For ERCP biliary cannulation, the usual techniques available in each center will be used, including advanced cannulation techniques if necessary. If biliary cannulation is not possible, a new ERCP attempt will be performed within a maximum of one month. If biliary cannulation is still not achieved, it will be counted as a technical failure.

    Procedure: Biliary sphincterotomy

  • No intervention
    Conservative treatment

    Patients allocated to this group will be discharged without any intervention. The inhospital management of patients with AP in the conservative treatment group, before and after randomization, will be under the care of their responsible physicians on the hospitalization wart at the corresponding collaborating center who will follow the management recommended by the clinical guidelines. Their discharge will be decided by their regular physician. Patients will be evaluated at one month, six months and one year and both clinical variables (clinical BPE recurrence) and quality of life will be assessed (quality of life by a survey- EORTC QLQ-C30,

Interventions

  • ProcedureBiliary sphincterotomy

    ERCP for biliary sphincterotomy will be performed during index admission for acute pancreatitis, prior to discharge or up till one month from discharge. The procedure will be performed after at least 6 hours of fasting during the index admission, by endoscopists in charge of performing ERCP as usual in the collaborating centers under sedation controlled by endoscopists or anesthesia according to the usual practice of the Endoscopy Unit of each collaborating center. For ERCP biliary cannulation, the usual techniques available in each center will be used, including advanced cannulation techniques if necessary. If biliary cannulation is not possible, a new ERCP attempt will be performed within a maximum of one month. If biliary cannulation is still not achieved, it will be it will be counted as a technical failure, maintaining the established clinical follow-up.

06

What researchers measure

Primary outcomes

  1. Biliopancreatic events (BPE)

    The primary aim is to assess the recurrence of the combined variable of biliopancreatic events (biliary colic, cholangitis, choledocholithiasis, acute cholecystitis or AP) of the endoscopic sphincterotomy strategy during the follow-up time after diagnosis of AP of biliary origin in inoperable patients with respect to conservative treatment.

    Time frame: From enrollment until 12 months after

Secondary outcomes

  1. Time to recurrence of BPE

    Time in days to recurrence of biliopancreatic events between both groups

    Time frame: From enrollment until 12 months after

  2. Recurrence of each of the variables that make up the combined variable BPE separately

    To assess the recurrence of each of the variables that make up the combined variable BPE separately and compare them between groups (AP, cholangitis, choledocholithiasis, cholecystitis, biliary colic).

    Time frame: From enrollment until 12 months after

  3. Technical success of biliary sphincterotomy

    Technical success will be defined as the achievement of biliary sphincterotomy defined by the endoscopist performing the procedure.

    Time frame: From enrollment until one month after

  4. Sphincterotomy related adverse events

    To describe the complications associated with sphincterotomy and the management of these adverse events of patients included in the study with the AGREE scale of endoscopic adverse events (Classification of Adverse events GastRointEstinal Endoscopy). This classification of adverse events ranges from 0 (no adverse events) until 5 (death) due to complications related to the procedure.

    Time frame: From enrollment until one month after

  5. Emergency room visits (BPE related)

    Number of visits to the emergency room due to a BPE

    Time frame: From enrollment until 12 months after

  6. Admission rate (BPE related)

    To evaluate differences between admission rate in hospital between both groups related to BPE

    Time frame: From enrollment until 12 months after

  7. Admission rate (not BPE related)

    Number of admissions (not directly associated to BPE) in hospital and comparison between both groups

    Time frame: From enrollment until 12 months after

  8. Emergency room visits (not BPE related)

    Number of emergency room visits that do not require admission and are not specifically related to BPE

    Time frame: From enrollment until 12 months after

  9. Mortality at 30 days

    Mortality at 30 days and comparison between both groups

    Time frame: From enrollment until one month after

  10. Hospital readmission at 30 days

    Hospital admission at day 30 due to EBP or not related to EBP and comparison between both groups

    Time frame: From enrollment until one month after

  11. Mortality at one year

    Evaluation of mortality at one year and comparison between both groups

    Time frame: From enrollment until 12 months after

  12. Index admission duration

    Days of index admission due to AP and comparison between both groups

    Time frame: From enrollment until one month after

  13. Quality of life during follow-up

    Quality of life will be assessed at every visit (1 month, 6 months and 12 months) with EORTC ( European Organization for Research and Treatment of Cancer ) Quality of Life Questionnaire C-30 and groups will be compared.The questionnaire is structured in 5 functional scales (physical functioning, activities of daily living, emotional functioning, cognitive functioning and social functioning), 3 symptom scales (fatigue, pain and nausea, vomiting), 1 global health status scale and, finally, 6 independent items (dyspnea, insomnia, anorexia, constipation, diarrhea and economic impact). Values between 1 and 4 (1: not at all, 2: a little, 3: quite a lot, 4: a lot) are assigned according to the patient's responses to the item, only items 29 and 30 are evaluated with scores from 1 to 7 (1: very bad, 7: excellent). The scores obtained are standardized and a score between 0 and 100 is obtained.

    Time frame: From enrollment until 12 months after

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jul 2027, 31 months after the start.

Of 92 non-industry interventional studies with no phase under Pancreatitis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's planned 31 months is close to that.

Counting every sponsor, half of 95 studies reached it within 32 months; a quarter within 23 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2024
First posted
May 10, 2024
StartActual
Dec 16, 2024
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Jan 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06409741
Lead sponsor
Hospital General Universitario de Alicante
Collaborators
Hospital Universitario Ramon y Cajal, Hospital del Rio Hortega, Hospital Universitario Reina Sofia de Cordoba, Hospital Clínico Universitario de Valencia
Responsible party
Jose Ramon Aparicio Tormo (Medical Doctor, Chief of Endoscopy Unit, Hospital General Universitario de Alicante) — Principal investigator
First posted
May 10, 2024
Start date
Dec 16, 2024
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jan 1, 2025

Study contacts

José R Aparicio, MD
principal investigator · Hospital General Universitario Dr. Balmis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion